Galapagos NV, a biotechnology company listed on Euronext and NASDAQ, announced the creation of a new subscription right plan aimed at compensating its senior management. On August 7, 2025, the company's Board of Directors approved "Subscription Right Plan 2025 $(B)$," which involves the creation of 1,800,000 subscription rights. These rights, subject to acceptance, allow senior management to subscribe to new Galapagos shares at an exercise price of €28.16 per share. The rights have an eight-year exercise term but cannot be exercised until the third anniversary of issuance. This plan is intended to align the interests of senior management with those of the shareholders by offering them a stake in the company's growth.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.